Redwood Scientific Technologies, Inc. (RSCI) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerRedwood Scientific Technologies, Inc. (RSCI) trades at $0.0001. Redwood Scientific Technologies, Inc. develops and markets over-the-counter FDA registered drugs using oral strip delivery technology. Sector: Healthcare.
Price as of · Last analyzed: Mar 17, 2026Analyst Coverage for RSCI: RSCI does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Redwood Scientific Technologies, Inc. (RSCI) Healthcare & Pipeline Overview
Redwood Scientific Technologies, Inc. specializes in developing and marketing over-the-counter, FDA-registered drugs utilizing innovative oral strip delivery technology. Based in Claremont, California, the company competes within the specialty and generic drug manufacturing sector, emphasizing accessible drug delivery methods. With a small team, RSCI focuses on niche market opportunities.
What Is the Investment Thesis for RSCI?
Redwood Scientific Technologies, Inc. presents a unique investment proposition within the specialty pharmaceutical sector, primarily driven by its innovative oral strip delivery technology for OTC drugs. The company's focus on improving drug administration and patient convenience could drive market adoption, particularly among consumers who prefer alternatives to traditional pills. However, potential investors may want to evaluate the company's small market capitalization of $0.00B and negative P/E ratio of -0.62, indicating current losses. Growth catalysts include successful development and launch of new OTC drugs utilizing the oral strip technology, as well as potential partnerships or licensing agreements. Key risks include competition from established pharmaceutical companies, regulatory hurdles, and the company's limited financial resources. The company's beta of -3.72 suggests high volatility and a negative correlation with the market, requiring careful risk management.
Based on FMP financials and quantitative analysis
RSCI Key Highlights
Redwood Scientific Technologies, Inc. specializes in over-the-counter (OTC) drugs using oral strip delivery technology.
- The company is based in Claremont, California, operating within the Drug Manufacturers - Specialty & Generic industry.
- Redwood Scientific Technologies, Inc. has a market capitalization of $0.00B.
- The company's Price-to-Earnings (P/E) ratio is -0.62, indicating it is not currently profitable.
- The company's beta is -3.72, suggesting a high level of volatility and inverse correlation to the market.
Who Are RSCI's Competitors?
RSCI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| MEDS TRxADE HEALTH, Inc. | $3.68 | -9.36% | $9.65M | — |
| MSLE Satellos Bioscience Inc. Common Stock | $8.50 | -0.12% | $11.0M | 33 5-pillar |
| NEUP Neuphoria Therapeutics Inc. | $3.47 | -1.14% | $18.8M | — |
| AIXC AIxCrypto Holdings, Inc. | $1.01 | -39.16% | $20.4M | — |
| RNTX Rein Therapeutics, Inc. | $0.80 | -6.03% | $22.4M | — |
| KYNB Kyntra Bio, Inc. | $6.31 | -2.92% | $25.5M | — |
| YI 111, Inc. | $3.22 | -2.57% | $28.1M | 39 5-pillar |
| PETS PetMed Express, Inc. | $1.36 | -0.73% | $29.1M | 32 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are RSCI's Key Strengths?
Innovative oral strip delivery technology.
- FDA-registered OTC drug products.
- Focus on patient convenience.
- Potential for rapid drug absorption.
What Are RSCI's Weaknesses?
Small market capitalization.
- Limited financial resources.
- Negative P/E ratio indicates current losses.
- High beta suggests high volatility.
What Are the Key Risks for RSCI?
Competition from established pharmaceutical companies with greater resources.
- Regulatory hurdles and compliance requirements for drug approvals.
- Product liability claims and litigation.
- Limited financial resources and small market capitalization.
- High beta indicates significant market volatility.
What Are RSCI's Competitive Advantages?
- Proprietary oral strip delivery technology.
- FDA-registered drug products.
- Focus on patient convenience and compliance.
- Niche market focus on alternative drug delivery methods.
What Does RSCI Do?
Redwood Scientific Technologies, Inc. is a pharmaceutical company focused on developing and marketing over-the-counter (OTC) drugs using an innovative oral strip delivery technology. Founded to improve drug administration and patient convenience, the company formulates its products as rapidly dissolving oral strips. These strips offer a discreet and easy-to-use alternative to traditional pills and capsules, potentially enhancing patient compliance and drug efficacy. Based in Claremont, California, Redwood Scientific Technologies operates within the specialty and generic drug manufacturing sector. The company's core business revolves around creating FDA-registered OTC drugs delivered via its proprietary oral strip technology. This technology allows for rapid absorption of the active ingredients, potentially leading to faster onset of action compared to conventional dosage forms. Redwood Scientific Technologies caters to consumers seeking convenient and accessible healthcare solutions. By focusing on OTC medications, the company aims to provide readily available treatments for common ailments without requiring a prescription. The oral strip delivery system is designed to appeal to individuals who have difficulty swallowing pills or prefer a more discreet method of drug administration. As a relatively small player in the pharmaceutical industry, Redwood Scientific Technologies faces competition from both large pharmaceutical companies and other specialty drug manufacturers. The company's success depends on its ability to innovate, secure regulatory approvals, and effectively market its products to consumers. The company's small size and limited resources also present challenges in terms of scaling operations and expanding its product portfolio.
What Products and Services Does RSCI Offer?
- Develops over-the-counter (OTC) drugs.
- Markets FDA-registered drugs.
- Utilizes oral strip delivery technology.
- Focuses on specialty and generic drug manufacturing.
- Offers convenient alternatives to traditional pills.
- Aims to improve patient compliance through innovative drug delivery.
How Does RSCI Make Money?
- Develops and manufactures OTC drugs using oral strip technology.
- Markets and sells products directly to consumers and through retail channels.
- Generates revenue through the sale of its OTC drug products.
What Industry Does RSCI Operate In?
Redwood Scientific Technologies operates within the specialty and generic drug manufacturing industry, a segment characterized by intense competition and evolving regulatory landscapes. The global market for generic drugs is projected to reach $480 billion by 2026, driven by increasing demand for affordable healthcare solutions and the expiration of patents on blockbuster drugs. The rise in self-medication trends and the increasing demand for user-friendly drug formulations are driving growth in the OTC market. Competitors like AAXT, CANQF, ETAOF, GENX, and ISHI operate in similar spaces, focusing on niche drug delivery systems and generic formulations. Redwood Scientific Technologies' oral strip technology positions it to capitalize on the demand for innovative and convenient drug delivery methods.
Who Are RSCI's Key Customers?
- Consumers seeking over-the-counter medications.
- Individuals who prefer alternatives to traditional pills.
- Patients who have difficulty swallowing pills.
- Consumers looking for convenient and discreet drug delivery methods.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
Redwood Scientific Technologies, Inc. operates in the Healthcare sector. It is headquartered in Claremont, US. RSCI has traded publicly since 2016.
RSCI Financials
RSCI Latest News
No recent news available for RSCI.
RSCI Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for RSCI.
Price Targets
Wall Street price target analysis for RSCI.
RSCI MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for RSCI; grades run from A+ (80-100) to F (below 30).
Leadership: Benjamin Lefrancois
Managing
Benjamin Lefrancois is the managing leader of Redwood Scientific Technologies, Inc. However, as the managing leader, he is responsible for overseeing the company's strategic direction, operations, and financial performance. His leadership is crucial for navigating the competitive pharmaceutical landscape and driving the company's growth.
Track Record: Due to limited information, Benjamin Lefrancois's specific achievements and strategic decisions at Redwood Scientific Technologies, Inc. cannot be detailed. His leadership is currently focused on guiding the company's development and marketing of over-the-counter FDA registered drugs through oral strip delivery technology. The success of the company's products and its ability to expand its market presence will be key indicators of his leadership effectiveness.
RSCI OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Redwood Scientific Technologies, Inc. may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited financial reporting and may not be subject to the same level of regulatory scrutiny as companies listed on major exchanges like the NYSE or NASDAQ. This tier is generally associated with higher risk and lower liquidity compared to higher-tiered OTC stocks and exchange-listed stocks.
- OTC Tier: OTC Other
- Limited financial disclosure and transparency.
- Low trading volume and liquidity.
- Potential for price manipulation and fraud.
- Higher risk of delisting or suspension of trading.
- Limited regulatory oversight and investor protection.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and regulatory approvals.
- Determine the company's capital structure and debt levels.
- Monitor trading volume and price volatility.
- Consult with a qualified financial advisor.
- FDA registration of drug products.
- Focus on over-the-counter medications.
- Use of oral strip delivery technology.
- Company is based in the United States.
- Operation in the healthcare sector.
Redwood Scientific Technologies, Inc. Healthcare Stock: Key Questions Answered
What do analysts say about RSCI stock?
As of 2026-03-17, there is no available analyst coverage or consensus on Redwood Scientific Technologies, Inc. (RSCI) stock. The company's small market capitalization of $0.00B and OTC Other tier listing likely contribute to the lack of analyst attention.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Limited information available on Redwood Scientific Technologies, Inc.
- OTC market carries higher risk than major exchanges.